MX2023002539A - Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). - Google Patents

Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).

Info

Publication number
MX2023002539A
MX2023002539A MX2023002539A MX2023002539A MX2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A MX 2023002539 A MX2023002539 A MX 2023002539A
Authority
MX
Mexico
Prior art keywords
conditions
mediated diseases
methods
pde
treating
Prior art date
Application number
MX2023002539A
Other languages
English (en)
Inventor
Vuk Koprivica
Original Assignee
Vanda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanda Pharmaceuticals Inc filed Critical Vanda Pharmaceuticals Inc
Publication of MX2023002539A publication Critical patent/MX2023002539A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La descripción proporciona métodos y composiciones para el tratamiento de enfermedades o afecciones mediadas por PDE IV, incluidas las enfermedades o afecciones inflamatorias, con el uso de un compuesto de Fórmula (I) o una sal farmacéuticamente aceptable del mismo.
MX2023002539A 2020-09-10 2021-09-10 Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv). MX2023002539A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063076774P 2020-09-10 2020-09-10
PCT/US2021/049870 WO2022056265A1 (en) 2020-09-10 2021-09-10 Methods of treating pde iv-mediated diseases or conditions

Publications (1)

Publication Number Publication Date
MX2023002539A true MX2023002539A (es) 2023-03-14

Family

ID=78080507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002539A MX2023002539A (es) 2020-09-10 2021-09-10 Metodos para tratar enfermedades o afecciones mediadas por fosfodiesterasa iv (pde iv).

Country Status (12)

Country Link
US (1) US20230364100A1 (es)
EP (1) EP4210674A1 (es)
JP (1) JP2023541261A (es)
KR (1) KR20230066350A (es)
CN (1) CN116507336A (es)
AU (1) AU2021338837A1 (es)
BR (1) BR112023004214A2 (es)
CA (1) CA3191177A1 (es)
CL (1) CL2023000648A1 (es)
IL (1) IL300628A (es)
MX (1) MX2023002539A (es)
WO (1) WO2022056265A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL375993A1 (en) 2002-09-16 2005-12-12 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
CN108848668B (zh) 2015-12-24 2022-04-26 加利福尼亚大学董事会 Cftr调节剂及其使用方法
KR20200044873A (ko) * 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물

Also Published As

Publication number Publication date
JP2023541261A (ja) 2023-09-29
EP4210674A1 (en) 2023-07-19
CN116507336A (zh) 2023-07-28
KR20230066350A (ko) 2023-05-15
IL300628A (en) 2023-04-01
AU2021338837A1 (en) 2023-04-06
CA3191177A1 (en) 2022-03-17
US20230364100A1 (en) 2023-11-16
BR112023004214A2 (pt) 2023-04-11
WO2022056265A1 (en) 2022-03-17
CL2023000648A1 (es) 2023-10-13

Similar Documents

Publication Publication Date Title
MX2023001689A (es) Inhibidores de bcl-2.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
CR20230310A (es) Inhibidores de prmt5
MX2020009372A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX2023001876A (es) Derivados de rapamicina.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2021011606A (es) Compuestos dirigidos a prmt5.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2024000299A (es) Compuestos antivirales.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MX2024001894A (es) Compuestos heterociclicos y metodos de uso.
MX2021007247A (es) Derivados de rapamicina.
MX2021012105A (es) Compuestos de pirrol.
MX2021015056A (es) Compuesto de pirrolopirimidina y uso del mismo.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
ZA202300912B (en) Tyk-2 inhibitor
MX2020002630A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta.
MX2024003952A (es) Combinación que comprende atogepant para tratar la migraña.
MX2022002446A (es) Compuestos de pirrolopirimidina inhibidores de perk.
SA521431048B1 (ar) مركبات بيروليدين